Medtronic has begun distribution of i-port Advance as part of a continued focus to provide meaningful therapy management solutions for people with diabetes.
i-port Advance can be used for people on insulin injection therapy who want to administer insulin conveniently while eliminating the need to puncture the skin with each dose of medication.
i-port Advance injection port is cleared by the FDA and indicated for patients who administer multiple daily subcutaneous injections of physician prescribed medications, including insulin.
The bandage-like device, which is roughly the size of a quarter, is designed to be changed every three days, accommodating multiple drug injections without the discomfort of additional needle sticks.
Medtronic vice president and general manager of insulin delivery for the Diabetes business Jeff Hubauer said, "Adding i-port Advance to our diabetes solutions portfolio puts us in a stronger position to support a broader group of people with diabetes – including those currently on injection therapy – with tools to help simplify diabetes management routines."
Medtronic acquired important assets from Patton Medical and is now the exclusive distributor of i-port Advance.
The device is now available for sale in the US, with expansion to additional global markets planned to take place over the next several months. The device is both FDA-cleared and CE marked.